Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Institut Paoli-Calmettes, Marseille, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Marseille
Treatments:ChemotherapyHospital:Institut Paoli-Calmettes
Drugs:Journal:Link
Date:Mar 2006

Description:

Patients: This phase II study involved a total of 105 patients and 98 who were eligible for a response with advanced pretreated platinum-sensitive ovarian cancer. The median age was 58.

Treatments: Patients received chemotherapy - paclitaxel followed by oxaliplatin every 21 days for a maximum of 9 cycles.

Toxicity: Toxicities included: grade 4 neutropenia, thrombocytopenia and hyperbilirubinemia and grade 3 neurotoxicity. In fact, a total of 67% of patients experienced grade 3-4 neutropenia.

Results: The overall survival was reported as 32.4 months.

Support: The study was supported by Sanofi-Synthelabo. This company manufactures and/or markets oxaliplatin.

Correspodence: Dr. A. Yovine





Back